home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

182.72 -3.70 (-1.98%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

24 25 Next >

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

April 10, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

April 03, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

April 01, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

What Analysts Are Saying About Axsome Therapeutics Stock ↗

March 19, 2024

Via Benzinga

What Analysts Are Saying About Axsome Therapeutics Stock ↗

February 27, 2024

Via Benzinga

Earnings Outlook For Axsome Therapeutics ↗

February 19, 2024

Via Benzinga

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List ↗

March 27, 2024

Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.

Via InvestorPlace

Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 26, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

March 25, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday? ↗

March 25, 2024

Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant reductions in cataplexy attacks, improved daytime wakefulness, and...

Via Benzinga

The Latest Analyst Ratings For Axsome Therapeutics ↗

February 06, 2024

Via Benzinga

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

March 25, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

March 25, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move ↗

March 23, 2024

The price could be right for these three biopharma stocks.

Via The Motley Fool

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

March 19, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

March 05, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

February 27, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 ↗

February 26, 2024

Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential.

Via InvestorPlace

3 Biotech Stocks to Buy and Hold for the Next 10 Years ↗

February 26, 2024

There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.

Via The Motley Fool

Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript ↗

February 20, 2024

AXSM earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones ↗

February 20, 2024

Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth.

Via Benzinga

Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug ↗

February 20, 2024

The company is testing a treatment for patients with agitation due to Alzheimer's disease.

Via Investor's Business Daily

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 20, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

2 Stocks That Could Double Your Money in 5 Years ↗

February 08, 2024

These market-beating stocks could be just getting started.

Via The Motley Fool

Earnings Scheduled For February 20, 2024 ↗

February 20, 2024

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion.

Via Benzinga

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst ↗

February 06, 2024

UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.

Via Benzinga

5 medical stocks growing earnings by triple digits

February 06, 2024

There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning

Via MarketBeat

Topics Economy

Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own' ↗

January 26, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK).

Via Benzinga

Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says ↗

January 25, 2024

Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates.

Via Benzinga

Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating ↗

January 23, 2024

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com